Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models

References

• Abe T, Unno M, Onogawa T, et al. (2001). LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689–1699
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, et al. (2007). Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903–910
   PubMed Web of Science ®Google Scholar
• Bailey J. (2005). Non-human primates in medical research and drug development: a critical review. Biog Amines 19:235–256
   Google Scholar
• Ballent M, Lifschitz A, Virkel G, et al. (2012). In vivo and ex vivo assessment of the interaction between ivermectin and danofloxacin in sheep. Vet J 192:422–427
   PubMed Web of Science ®Google Scholar
• Ballent M, Maté L, Virkel G, et al. (2014). Intestinal drug transport: ex vivo evaluation of the interactions between ABC transporters and anthelmintic molecules. J Vet Pharmacol Ther 37:332--337
   PubMed Web of Science ®Google Scholar
• Barbier O, Bélanger A. (2003). The cynomolgus monkey (Macaca fascicularis) is the best animal model for the study of steroid glucuronidation. J Steroid Biochem Mol Biol 85:235–245
   PubMed Web of Science ®Google Scholar
• Bateman TJ, Reddy VG, Kakuni M, et al. (2014). Application of chimeric mice with humanized liver for study of human-specific drug metabolism. Drug Metab Dispos 42:1055–1065
   PubMed Web of Science ®Google Scholar
• Bleasby K, Castle J, Roberts C, et al. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica 36:963–988
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Bertrand M, Jackson P, et al. (2000). Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152
   PubMed Web of Science ®Google Scholar
• Brandon EF, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicol Appl Pharmacol 189:233–246
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D, et al. (2004). Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug–drug interactions. Cancer Res 64:5804–5811
   PubMed Web of Science ®Google Scholar
• Carr B, Norcross R, Fang Y, et al. (2006). Characterization of the rhesus monkey CYP3A64 enzyme: Species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703–1712
   PubMed Web of Science ®Google Scholar
• Chan AW. (2013). Progress and prospects for genetic modification of nonhuman primate models in biomedical research. ILAR J 54:211–223
   PubMed Web of Science ®Google Scholar
• Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4
   PubMed Web of Science ®Google Scholar
• Cheung C, Gonzalez FJ. (2008). Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327:288–299
   PubMed Web of Science ®Google Scholar
• Cheung C, Yu AM, Ward JM, et al. (2005). The cyp2e1-humanized transgenic mouse: Role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos 33:449–457
   PubMed Web of Science ®Google Scholar
• Chu X, Bleasby K, Evers R. (2013). Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 9:237–252
   PubMed Web of Science ®Google Scholar
• Chu X, Zhang Z, Yabut J, et al. (2012). Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. Mol Pharmacol 81:220--227
   Google Scholar
• Cohen J. (2014). Toxicology. ‘Humanized’ mouse detects deadly drug side effects. Science 344:244–245
   Google Scholar
• Cvetkovic M, Leake B, Fromm MF, et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866--871
   Google Scholar
• Dahan A, Amidon GL. (2010). MRP2 mediated drug–drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 386:216–220
   PubMed Web of Science ®Google Scholar
• Dandri M, Burda MR, Torok E, et al. (2001). Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatol 33:981–988
   PubMed Web of Science ®Google Scholar
• David RA, Rushmore TH. (2002). Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr Drug Metab 3:289–309
   PubMed Web of Science ®Google Scholar
• Dawson PA, Hubbert ML, Rao A. (2010). Getting the mOST from OST: role of organic solute transporter, OSTα-OSTβ, in bile acid and steroid metabolism. Biochim Biophys Acta 1801:994–1004
   PubMed Web of Science ®Google Scholar
• De Buck SS, Sinha VK, Fenu LA, et al. (2007). Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766–1780
   PubMed Web of Science ®Google Scholar
• Devoy A, Bunton-Stasyshyn RK, Tybulewicz VL, et al. (2012). Genomically humanized mice: Technologies and promises. Nat Rev Genet 13:14–20
   Web of Science ®Google Scholar
• Dickins M, Van De Waterbeemd H. (2004). Simulation models for drug disposition and drug interactions. Drug Discov Today Biosilico 2:38–45
   Google Scholar
• Di L, Trapa P, Obach RS, et al. (2012). A novel relay method for determining low-clearance values. Drug Metab Dispos 40:1860–1865
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Castell JV, et al. (2008). Cell lines: A tool for in vitro drug metabolism studies. Curr Drug Metab 9:1–11
   PubMed Web of Science ®Google Scholar
• Ekins S, Wrighton SA. (2001). Application of in silico approaches to predicting drug–drug interactions. J Pharmacol Toxicol Methods 45:65–69
   PubMed Web of Science ®Google Scholar
• EMA, (2012). Guideline on the Investigation of Drug Interactions [Online]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf. [last accessed 10 Apr 2014]
   Google Scholar
• Emoto C, Yoda N, Uno Y, et al. (2013). Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 Identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Curr Drug Metab 14:239–252
   PubMed Web of Science ®Google Scholar
• Faed EM. (1984). Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 15:1213–1249
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Boldt S, Kish M, et al. (2008). Prediction of drug–drug interactions from in vitro induction data: Application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36:1971–1974
   PubMed Web of Science ®Google Scholar
• Fanelli G, Bohn D, Zacchei A. (1977). Renal excretion of a slauretic-uricosuric agent (MK-196) and interaction with a urate-retaining drug, pyrazinoate, in the chimpanzee. J Pharmacol Exp Ther 200:413–419
   PubMed Web of Science ®Google Scholar
• Felmlee MA, Lon HK, Gonzalez FJ, et al. (2008). Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36:435–441
   PubMed Web of Science ®Google Scholar
• Foster JR, Lund G, Sapelnikova S, et al. (2014). Chimeric rodents with humanized liver: Bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 44:109–122
   PubMed Web of Science ®Google Scholar
• Foti RS, Rock DA, Wienkers LC, et al. (2010). Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981–987
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon M, Donato M, Castell J, et al. (2003). Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292–312
   PubMed Web of Science ®Google Scholar
• Granvil CP, Yu AM, Elizondo G, et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548–558
   PubMed Web of Science ®Google Scholar
• Grimsley A, Gallagher R, Hutchison M, et al. (2013). Drug–drug interactions and metabolism in cytochrome P450 2C knockout mice: Application to troleandomycin and midazolam. Biochem Pharmacol 86:529–538
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Turvy CG. (1991). Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256:1189–1194
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kapelyukh Y, Tahara H, et al. (2011). Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug–drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518–528
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Tahara H, Inoue R, et al. (2012). Investigation of drug–drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. Drug Metab Dispos 40:474–480
   PubMed Web of Science ®Google Scholar
• Hayton WL, Levy G. (1971). Effect of SKF 525-A on drug absorption in rats. Life Sci 10:691–697
   Google Scholar
• HGNC. (2014). HGNC gene families/groupings nomenclature [Online]. Available from: http://www.genenames.org/genefamilies/a-z [last accessed 06 Sep 2014]
   Google Scholar
• Holmstock N, Gonzalez FJ, Baes M, et al. (2013). PXR/CYP3A4-humanized mice for studying drug–drug interactions involving intestinal P-glycoprotein. Mol Pharm 10:1056–1062
   PubMed Web of Science ®Google Scholar
• Honma W, Kamiyama Y, Yoshinari K, et al. (2001). Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos 29:274–281
   PubMed Web of Science ®Google Scholar
• Hsiao P, Bui T, Ho RJ, et al. (2008). In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos 36:481–484
   PubMed Web of Science ®Google Scholar
• Hyland R, Dickins M, Collins C, et al. (2008). Maraviroc: In vitro assessment of drug–drug interaction potential. Br J Clin Pharmacol 66:498–507
   PubMed Web of Science ®Google Scholar
• Igarashi Y, Tateno C, Tanaka Y, et al. (2008). Engraftment of human hepatocytes in the livers of rats bearing bone marrow reconstructed with immunodeficient mouse bone marrow cells. Xenotransplantation 15:235–245
   PubMed Web of Science ®Google Scholar
• Ito M, Kobayashi K, Nakahata T. (2008). NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol 324:53–76
   PubMed Web of Science ®Google Scholar
• Jancova P, Anzenbacher P, Anzenbacherova E. (2010). Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103–116
   PubMed Web of Science ®Google Scholar
• Jiang X-L, Gonzalez FJ, Yu A-M. (2011). Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev 43:27–40
   PubMed Web of Science ®Google Scholar
• Kakuni M, Yamasaki C, Tachibana A, et al. (2014). Chimeric mice with humanized livers: A unique tool for in vivo and in vitro enzyme induction studies. Int J Mol Sci 15:58–74
   Web of Science ®Google Scholar
• Kanazu T, Yamaguchi Y, Okamura N, et al. (2004). Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391–402
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–1410
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Okumura H, et al. (2005). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333–1340
   PubMed Web of Science ®Google Scholar
• Katoh M, Sawada T, Soeno Y, et al. (2007). In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 96:428–437
   PubMed Web of Science ®Google Scholar
• Katoh M, Tateno C, Yoshizato K, et al. (2008). Chimeric mice with humanized liver. Toxicol 246:9–17
   PubMed Web of Science ®Google Scholar
• Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145–157
   PubMed Web of Science ®Google Scholar
• Kemper EM, Van Zandbergen AE, Cleypool C, et al. (2003). Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849–2855
   PubMed Web of Science ®Google Scholar
• Kim S, Dinchuk JE, Anthony MN, et al. (2010). Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metab Dispos 38:16–24
   PubMed Web of Science ®Google Scholar
• Kim S, Pray D, Zheng M, et al. (2008). Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: Extrapolation to human CYP3A4 induction potential. Drug Metab Lett 2:169–175
   PubMedGoogle Scholar
• King C, Finley B, Franklin R. (2000). The glucuronidation of morphine by dog liver microsomes: Identification of morphine-6-O-glucuronide. Drug Metab Dispos 28:661–663
   PubMed Web of Science ®Google Scholar
• Komatsu K, Ito K, Nakajima Y, et al. (2000). Prediction of in vivo drug–drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos 28:475–481
   PubMed Web of Science ®Google Scholar
• Kumar S, Kwei GY, Poon GK, et al. (2003). Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: Role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 304:1161–1171
   PubMed Web of Science ®Google Scholar
• Kuroha M, Kayaba H, Kishimoto S, et al. (2002). Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91:868–873
   PubMed Web of Science ®Google Scholar
• Lai Y. (2009). Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin Drug Metab Toxicol 5:1175–1187
   PubMed Web of Science ®Google Scholar
• Lake BG, Ball SE, Kao J, et al. (2002). Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835–847
   PubMed Web of Science ®Google Scholar
• Leape LL, Bates DW, Cullen DJ, et al. (1995). Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 274:35–43
   PubMed Web of Science ®Google Scholar
• Lentz KA, Quitko M, Morgan DG, et al. (2007). Development and validation of a preclinical food effect model. J Pharm Sci 96:459–472
   PubMed Web of Science ®Google Scholar
• Li AP, Maurel P, Gomez-Lechon MJ, et al. (1997). Preclinical evaluation of drug–drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem-Biol Interact 107:5–16
   PubMed Web of Science ®Google Scholar
• Lin JH. (1995). Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008–1021
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Chen I-W, et al. (1999). Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction. Drug Metab Dispos 27:1187–1193
   PubMed Web of Science ®Google Scholar
• Ma X, Cheung C, Krausz KW, et al. (2008). A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 36:2506–2512
   PubMed Web of Science ®Google Scholar
• Ma X, Shah Y, Cheung C, et al. (2007). The Pregnane X receptor gene-humanized mouse: A model for investigating drug–drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194–200
   PubMed Web of Science ®Google Scholar
• Mandlekar SV, Rose AV, Cornelius G, et al. (2007). Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica 37:923–942
   PubMed Web of Science ®Google Scholar
• Manis JP. (2007). Knock out, knock in, knock down-genetically manipulated mice and the Nobel Prize. N Engl J Med 357:2426–2429
   PubMed Web of Science ®Google Scholar
• Mao J, Johnson TR, Shen Z, et al. (2013). Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: Comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 41:343–352
   PubMed Web of Science ®Google Scholar
• Marathe PH, Rodrigues AD. (2006). In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug–drug interactions. Curr Drug Metab 7:687–704
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, De Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894
   PubMed Web of Science ®Google Scholar
• Mercer DF, Schiller DE, Elliott JF, et al. (2001). Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7:927–933
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, et al. (2002). Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866–874
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Sinal CJ. (2008). Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ther 83:818–828
   PubMed Web of Science ®Google Scholar
• Nishimura M, Yokoi T, Tateno C, et al. (2005). Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 20:121–126
   PubMedGoogle Scholar
• Nishimura T, Hu Y, Wu M, et al. (2013). Using chimeric mice with humanized livers to predict human drug metabolism and a drug–drug interaction. J Pharmacol Exp Ther 344:388–396
   PubMed Web of Science ®Google Scholar
• Niu Y, Shen B, Cui Y, et al. (2014). Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156:836–843
   PubMed Web of Science ®Google Scholar
• Ogasawara A, Kume T, Kazama E. (2007). Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410–418
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, et al. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug Metab Dispos 34:191–197
   PubMed Web of Science ®Google Scholar
• Oguri K, Kurogi A, Yamabe K, et al. (1996). Purification of a phenobarbital-inducible UDP-glucuronosyltransferase isoform from dog liver which catalyzes morphine and testosterone glucuronidation. Arch Biochem Biophys 325:159–166
   PubMed Web of Science ®Google Scholar
• Okumura H, Katoh M, Sawada T, et al. (2007). Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533–538
   PubMed Web of Science ®Google Scholar
• Ouyang EC, Wu CH, Walton C, et al. (2001). Transplantation of human hepatocytes into tolerized genetically immunocompetent rats. World J Gastroenterol 7:324–330
   PubMed Web of Science ®Google Scholar
• Pasanen M. (2009). Species differences in CYP enzymes. Monografías de la Real Academia Nacional de Farmacia Monografía XIV:63–90
   Google Scholar
• Peltz G. (2013). Can ‘humanized’ mice improve drug development in the 21st century? Trends Pharmacol Sci 34:255–260
   PubMed Web of Science ®Google Scholar
• Polasek TM, Miners JO. (2006). Quantitative prediction of macrolide drug–drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 62:203–208
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T. (2010). Use of in vivo animal models to assess drug–drug interactions. In: Pang KS, Rodrigues AD, Peter RM, eds. Enzyme- and transporter-based drug–drug interactions. New York: Springer, 283–297
   Google Scholar
• Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, et al. (2011). Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 20:772–777
   PubMed Web of Science ®Google Scholar
• Rabba AK, Si L, Xue K, et al. (2011). In situ intestinal perfusion of irinotecan: Application to P-gp mediated drug interaction and introduction of an improved HPLC assay. J Pharm Pharm Sci 14:138–147
   PubMed Web of Science ®Google Scholar
• Rekic D, Roshammar D, Mukonzo J, et al. (2011). In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 71:536–543
   PubMed Web of Science ®Google Scholar
• Rendic S. (2002). Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 34:83–448
   PubMed Web of Science ®Google Scholar
• Ripp SL, Mills JB, Fahmi OA, et al. (2006). Use of immortalized human hepatocytes to predict the magnitude of clinical drug–drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742–1748
   PubMed Web of Science ®Google Scholar
• Robinet E, Baumert TF. (2011). A first step towards a mouse model for hepatitis C virus infection containing a human immune system. J Hepatol 55:718–720
   PubMed Web of Science ®Google Scholar
• Rosenthal N, Brown S. (2007). The mouse ascending: perspectives for human-disease models. Nat Cell Biol. 9:993–999
   PubMed Web of Science ®Google Scholar
• Salyers KL, Xu Y. (2012). Animal models for studying drug metabolizing enzymes and transporters. In: Zhang D, Surapaneni S, eds. ADME-enabling technologies in drug design and development. New Jersey: John Wiley & Sons Inc, 253–276
   Google Scholar
• Sasaki M, Suzuki H, Aoki J, et al. (2004). Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 66:450--459
   Google Scholar
• Scheer N, Balimane P, Hayward MD, et al. (2012a). Generation and characterization of a novel multidrug resistance protein 2 humanized mouse line. Drug Metab Dispos 40:2212–2218
   PubMed Web of Science ®Google Scholar
• Scheer N, Kapelyukh Y, Chatham L, et al. (2012b). Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 82:1022–1029
   PubMed Web of Science ®Google Scholar
• Scheer N, Kapelyukh Y, Mcewan J, et al. (2012c). Modeling human cytochrome P450 2D6 metabolism and drug–drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63–72
   PubMed Web of Science ®Google Scholar
• Scheer N, Ross J, Rode A, et al. (2008). A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228–3239
   PubMed Web of Science ®Google Scholar
• Scheer N, Snaith M, Wolf CR, et al. (2013). Generation and utility of genetically humanized mouse models. Drug Discov Today 18:1200–1211
   PubMed Web of Science ®Google Scholar
• Scheer N, Wolf CR. (2013). Xenobiotic receptor humanized mice and their utility. Drug Metab Rev 45:110–121
   PubMed Web of Science ®Google Scholar
• Scheer N, Wolf CR. (2014). Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica 44:96–108
   PubMed Web of Science ®Google Scholar
• Seneca N, Zoghbi SS, Shetty HU, et al. (2010). Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice. Nucl Med Biol 37:335–345
   PubMed Web of Science ®Google Scholar
• Sharma P, Butters CJ, Smith V, et al. (2012). Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci 47:244–255
   PubMed Web of Science ®Google Scholar
• Sharma P, Holmes VE, Elsby R, et al. (2010). Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions. Xenobiotica 40:24–37
   PubMed Web of Science ®Google Scholar
• Shen H, Yang Z, Mintier G, et al. (2013). Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: In vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther 344:673–685
   PubMed Web of Science ®Google Scholar
• Shen HW, Jiang XL, Gonzalez FJ, et al. (2011). Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. Curr Drug Metab 12:997–1006
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, et al. (2004). Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236
   PubMed Web of Science ®Google Scholar
• Sinz M, Wallace G, Sahi J. (2008). Current industrial practices in assessing CYP450 enzyme induction: Preclinical and clinical. AAPS J 10:391–400
   PubMed Web of Science ®Google Scholar
• Smith JA, Boyd KM. (2002). The Boyd Group papers on the use of non-human primates in research and testing [Online]. Available from: http://www.boyd-group.demon.co.uk/Prefaceandsummary.pdf. [last accessed 10 Apr 2014]
   Google Scholar
• Strom SC, Davila J, Grompe M. (2010). Chimeric mice with humanized liver: Tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491–509
   PubMedGoogle Scholar
• Suemizu H, Hasegawa M, Kawai K, et al. (2008). Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 377:248–252
   PubMed Web of Science ®Google Scholar
• Tachibana A, Tateno C, Yoshizato K. (2013). Repopulation of the immunosuppressed retrorsine-treated infant rat liver with human hepatocytes. Xenotransplantation 20:227–238
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kato M, Takano J, et al. (2010). Predicting drug–drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11:762–777
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Chida M, et al. (2006). Is the monkey an appropriate animal model to examine drug–drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 316:1187–1194
   PubMed Web of Science ®Google Scholar
• Tahara H, Shono M, Kusuhara H, et al. (2005). Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res 22:647–660
   PubMed Web of Science ®Google Scholar
• Tang C, Prueksaritanont T. (2010). Use of in vivo animal models to assess pharmacokinetic drug–drug interactions. Pharm Res 27:1772–1787
   PubMed Web of Science ®Google Scholar
• Tanoue C, Sugihara K, Uramaru N, et al. (2013). Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes. Xenobiotica 43:956–962
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–912
   PubMed Web of Science ®Google Scholar
• Uno Y, Murayama N, Kunori M, et al. (2013). Systematic identification and characterization of glutathione S-transferases in cynomolgus macaque. Biochem Pharmacol 86:679–690
   PubMed Web of Science ®Google Scholar
• Uno Y, Ohuchi T, Uehara S, et al. (2009). Sex-related differences in the expression of mfGSTA2, a novel GST identified in cynomolgus monkey (Macaca fascicularis). Drug Metab Dispos 37:453–456
   PubMed Web of Science ®Google Scholar
• Uno Y, Suzuki Y, Wakaguri H, et al. (2008). Expressed sequence tags from cynomolgus monkey (Macaca fascicularis) liver: A systematic identification of drug-metabolizing enzymes. FEBS Lett 582:351–358
   PubMed Web of Science ®Google Scholar
• USFDA. (2009). Preventable adverse drug reactions: A focus on drug interactions [Online]. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm#Types of Drug Interactions [last sccessed 10 Apr 2014]
   Google Scholar
• USFDA. (2010). Drugs removed from or restricted in the U.S. market because of drug interactions [Online]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm115979.htm [last accessed 10 Apr 2014]
   Google Scholar
• USFDA. (2012). Guidance for industry drug interaction studies – Study design, data analysis, implications for dosing, and labeling recommendations [Online]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf [last accessed 10 Apr 2014]
   Google Scholar
• Van De Steeg E, Wagenaar E, Van Der Kruijssen CM, et al. (2010). Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 120:2942–2952
   PubMed Web of Science ®Google Scholar
• Van Waterschoot RA, Rooswinkel RW, Sparidans RW, et al. (2009). Inhibition and stimulation of intestinal and hepatic CYP3A activity: Studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305–2313
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Granda BW, Grassi JM, et al. (2004). Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos 32:800–804
   PubMed Web of Science ®Google Scholar
• Ward KW, Coon DJ, Magiera D, et al. (2009). Exploration of the African green monkey as a preclinical pharmacokinetic model: Oral pharmacokinetic parameters and drug–drug interactions. Xenobiotica 39:266–272
   PubMed Web of Science ®Google Scholar
• Ward KW, Stelman GJ, Morgan JA, et al. (2004). Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 32:172–177
   PubMed Web of Science ®Google Scholar
• Washburn ML, Bility MT, Zhang L, et al. (2011). A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 140:1334–1344
   PubMed Web of Science ®Google Scholar
• Wenning Q, Stock Jl, Sacca. R, (2012). Humanized mouse models in drug discovery research [Online]. Available from: http://www.americanpharmaceuticalreview.com/Featured-Articles/115292-Humanized-Mouse-Models-in-Drug-Discovery-Research/ [last accessed 10 Apr 2014]
   Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833
   PubMed Web of Science ®Google Scholar
• Wildman DE. (2002). A map of the common chimpanzee genome. BioEssays 24:490–493
   PubMed Web of Science ®Google Scholar
• Williams ET, Schouest KR, Leyk M, et al. (2007). The chimpanzee cytochrome P450 3A subfamily: Is our closest related species really that similar? Comp Biochem Physiol Part D Genomics Proteomics 2:91–100
   PubMed Web of Science ®Google Scholar
• Wise J. (2013). Polypharmacy: A necessary evil. BMJ 347:f7033
   PubMed Web of Science ®Google Scholar
• Wong H, Grossman SJ, Bai SA, et al. (2004). The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: Model characterization and application. Drug Metab Dispos 32:1359–1369
   PubMed Web of Science ®Google Scholar
• Wong H, Wong H, GraceJr J, et al. (2006). Glucuronidation in the chimpanzee (Pan troglodytes): Studies with acetaminophen, oestradiol and morphine. Xenobiotica 36:1178–1190
   PubMed Web of Science ®Google Scholar
• Xie W, Barwick JL, Downes M, et al. (2000). Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435–439
   PubMed Web of Science ®Google Scholar
• Xu L, Das B, Prakash C, et al. (2011). CYP450 Enzymes in drug discovery and development an overview. In: Lyubimov AV, ed. Encyclopedia of drug metabolism and interactions. New Jersey: John Wiley & Sons Inc, 1–35
   Google Scholar
• Xu D, Nishimura T, Nishimura S, et al. (2014). Fialuridine induces acute liver failure in chimeric TK-NOG mice: A model for detecting hepatic drug toxicity prior to human testing. PLoS Med 11:e1001628
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Murayama N, et al. (2013). In vivo drug interactions of the teratogen thalidomide with midazolam: Heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol 26:486–489
   PubMed Web of Science ®Google Scholar
• Yao C, Levy RH. (2002). Inhibition-based metabolic drug–drug interactions: predictions from in vitro data. J Pharm Sci 91:1923–1935
   PubMed Web of Science ®Google Scholar
• Yeung CK, Fujioka Y, Hachad H, et al. (2011). Are circulating metabolites important in drug–drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105–113
   PubMed Web of Science ®Google Scholar
• Yoshitsugu H, Nishimura M, Tateno C, et al. (2006). Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 21:465–474
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome p450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–1319
   PubMed Web of Science ®Google Scholar
• Zhang D, Luo G, Ding X, et al. (2012). Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmaceutica Sinica B 2:549–561
   Google Scholar
• Zhang L, Strong JM, Qiu W, et al. (2006). Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62–69
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, et al. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710
   PubMed Web of Science ®Google Scholar
• Zhou XE, Xu HE. (2008). Structure and function of PXR and CAR. In: Xie W, ed. Nuclear receptors in drug metabolism. New Jersey: John Wiley & Sons Inc, 147–166
   Google Scholar
• Zoghbi SS, Liow JS, Yasuno F, et al. (2008). 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649–656
   PubMed Web of Science ®Google Scholar